Host |
Mouse |
Clone |
DE2B4 |
Format |
Purified |
Method |
WB, P, IP |
Pretreatment |
Enzyme |
Positive control |
Alzheimer´s disease brain |
Isotype |
Mouse IgG1 |
Immunogen |
Synthetic peptide consisting of residues 1-17 of the amyloid beta protein |
Amyloid Beta
|
Zytomed Systems |
DE2B4 |
100 µg |
Purified |
RUO |
601-0210 |
-
|
Host |
Rabbit |
Clone |
polyclonal |
Format |
Serum |
Method |
EL, WB, P |
Pretreatment |
Formic acid |
Positive control |
Alzheimer´s disease brain |
Isotype |
Rabbit IgG |
Amyloid Beta 1 - 40
|
Zytomed Systems |
polyclonal |
100 µl |
Serum |
RUO |
601-0211 |
-
|
Host |
Rabbit |
Clone |
polyclonal |
Format |
Serum |
Method |
EL, WB, P |
Pretreatment |
Formic acid |
Positive control |
Alzheimer´s disease brain |
Isotype |
Rabbit IgG |
Amyloid Beta 1 - 42
|
Zytomed Systems |
polyclonal |
100 µl |
Serum |
RUO |
601-0212 |
-
|
Host |
Mouse |
Clone |
BAM-10 |
Format |
Concentrate |
Method |
F, P |
Positive control |
Brain |
Dilution |
1:50 - 1:100 |
Isotype |
Mouse IgG1 |
Localization |
Cytoplasm |
Amyloid Beta Protein
|
Diagnostic Biosystems |
BAM-10 |
1 ml |
Concentrate |
CE/IVD |
MOB410 |
-
|
Host |
Mouse |
Clone |
BAM-10 |
Format |
Concentrate |
Method |
F, P |
Positive control |
Brain |
Dilution |
1:50 - 1:100 |
Isotype |
Mouse IgG1 |
Localization |
Cytoplasm |
Amyloid Beta Protein
|
Diagnostic Biosystems |
BAM-10 |
0.1 ml |
Concentrate |
CE/IVD |
MOB410-01 |
-
|
Host |
Mouse |
Clone |
BAM-10 |
Format |
Concentrate |
Method |
F, P |
Positive control |
Brain |
Dilution |
1:50 - 1:100 |
Isotype |
Mouse IgG1 |
Localization |
Cytoplasm |
Amyloid Beta Protein
|
Diagnostic Biosystems |
BAM-10 |
0.5 ml |
Concentrate |
CE/IVD |
MOB410-05 |
-
|
Host |
Mouse |
Clone |
AR 441 |
Format |
Concentrate |
Method |
F, P |
Pretreatment |
Citrate |
Positive control |
Prostate Carcinoma |
Dilution |
1:25 - 1:50 |
Isotype |
Mouse IgG1 |
Localization |
Nucleus |
Androgen Receptor
|
Diagnostic Biosystems |
AR 441 |
1 ml |
Concentrate |
CE/IVD |
MOB245 |
-
|
Host |
Mouse |
Clone |
AR 441 |
Format |
Concentrate |
Method |
F, P |
Pretreatment |
Citrate |
Positive control |
Prostate Carcinoma |
Dilution |
1:25 - 1:50 |
Isotype |
Mouse IgG1 |
Localization |
Nucleus |
Androgen Receptor
|
Diagnostic Biosystems |
AR 441 |
0.1 ml |
Concentrate |
CE/IVD |
MOB245-01 |
-
|
Host |
Mouse |
Clone |
AR 441 |
Format |
Concentrate |
Method |
F, P |
Pretreatment |
Citrate |
Positive control |
Prostate Carcinoma |
Dilution |
1:25 - 1:50 |
Isotype |
Mouse IgG1 |
Localization |
Nucleus |
Androgen Receptor
|
Diagnostic Biosystems |
AR 441 |
0.5 ml |
Concentrate |
CE/IVD |
MOB245-05 |
-
|
Host |
Mouse |
Clone |
AR 441 |
Format |
Ready-to-use |
Method |
F, P |
Pretreatment |
Citrate |
Positive control |
Prostate Carcinoma |
Dilution |
- |
Isotype |
Mouse IgG1 |
Localization |
Nucleus |
Androgen Receptor
|
Diagnostic Biosystems |
AR 441 |
6 ml |
Ready-to-use |
CE/IVD |
PDM167 |
-
|
Host |
Rabbit |
Clone |
ZR334 |
Format |
Concentrate |
Reactivity |
- |
Method |
P |
Pretreatment |
Citrate or EDTA |
Positive control |
Prostate or Breast Carcinoma |
Dilution |
1:100 - 1:200 |
Isotype |
IgG |
Immunogen |
Synthetic peptide corresponding ti residues (within aa 1-100) of human Androgen Receptor |
Localization |
Nucleus |
Androgen Receptor (AR)
|
Zeta Corporation |
ZR334 |
1 ml |
Concentrate |
CE/IVD |
Z2640RL |
-
|
Host |
Rabbit |
Clone |
ZR334 |
Format |
Ready-to-use |
Reactivity |
- |
Method |
P |
Pretreatment |
Citrate or EDTA |
Positive control |
Prostate or Breast Carcinoma |
Dilution |
- |
Isotype |
IgG |
Immunogen |
Synthetic peptide corresponding ti residues (within aa 1-100) of human Androgen Receptor |
Localization |
Nucleus |
Androgen Receptor (AR)
|
Zeta Corporation |
ZR334 |
7 ml |
Ready-to-use |
CE/IVD |
Z2640RP |
-
|
Host |
Rabbit |
Clone |
ZR334 |
Format |
Concentrate |
Reactivity |
- |
Method |
P |
Pretreatment |
Citrate or EDTA |
Positive control |
Prostate or Breast Carcinoma |
Dilution |
1:100 - 1:200 |
Isotype |
IgG |
Immunogen |
Synthetic peptide corresponding ti residues (within aa 1-100) of human Androgen Receptor |
Localization |
Nucleus |
Androgen Receptor (AR)
|
Zeta Corporation |
ZR334 |
0.5 ml |
Concentrate |
CE/IVD |
Z2640RS |
-
|
Host |
Rabbit |
Clone |
ZR334 |
Format |
Concentrate |
Reactivity |
- |
Method |
P |
Pretreatment |
Citrate or EDTA |
Positive control |
Prostate or Breast Carcinoma |
Dilution |
1:100 - 1:200 |
Isotype |
IgG |
Immunogen |
Synthetic peptide corresponding ti residues (within aa 1-100) of human Androgen Receptor |
Localization |
Nucleus |
Androgen Receptor (AR)
|
Zeta Corporation |
ZR334 |
0.1 ml |
Concentrate |
CE/IVD |
Z2640RT |
-
|
Host |
Rabbit |
Clone |
polyclonal |
Format |
Purified |
Method |
WB, P |
Pretreatment |
Citrate |
Isotype |
Rabbit IgG |
Immunogen |
Synthetic peptide corresponding to a sequence within the amino acid terminus of human ACE2 |
Angiotensin Converting Enzyme 2 (ACE2)
|
Zytomed Systems |
polyclonal |
100 µg |
Purified |
RUO |
601-0006 |
-
|
Host |
Monospecific Mouse |
Clone |
ZM211 |
Format |
Concentrate |
Reactivity |
- |
Method |
P |
Pretreatment |
Citrate or EDTA |
Positive control |
Lymph node or hairy cell leukemia |
Dilution |
1:100 - 1:200 |
Isotype |
IgG2a /κ |
Immunogen |
Recombinant full-length human Annexin A1 protein |
Localization |
Nucleus, cytoplasm or cell membrane |
Annexin A1
|
Zeta Corporation |
ZM211 |
1 ml |
Concentrate |
CE/IVD |
Z2488ML |
-
|
Host |
Monospecific Mouse |
Clone |
ZM211 |
Format |
Ready-to-use |
Reactivity |
- |
Method |
P |
Pretreatment |
Citrate or EDTA |
Positive control |
Lymph node or hairy cell leukemia |
Dilution |
- |
Isotype |
IgG2a /κ |
Immunogen |
Recombinant full-length human Annexin A1 protein |
Localization |
Nucleus, cytoplasm or cell membrane |
Annexin A1
|
Zeta Corporation |
ZM211 |
7 ml |
Ready-to-use |
CE/IVD |
Z2488MP |
-
|
Host |
Monospecific Mouse |
Clone |
ZM211 |
Format |
Concentrate |
Reactivity |
- |
Method |
P |
Pretreatment |
Citrate or EDTA |
Positive control |
Lymph node or hairy cell leukemia |
Dilution |
1:100 - 1:200 |
Isotype |
IgG2a /κ |
Immunogen |
Recombinant full-length human Annexin A1 protein |
Localization |
Nucleus, cytoplasm or cell membrane |
Annexin A1
|
Zeta Corporation |
ZM211 |
0.5 ml |
Concentrate |
CE/IVD |
Z2488MS |
-
|
Host |
Monospecific Mouse |
Clone |
ZM211 |
Format |
Concentrate |
Reactivity |
- |
Method |
P |
Pretreatment |
Citrate or EDTA |
Positive control |
Lymph node or hairy cell leukemia |
Dilution |
1:100 - 1:200 |
Isotype |
IgG2a /κ |
Immunogen |
Recombinant full-length human Annexin A1 protein |
Localization |
Nucleus, cytoplasm or cell membrane |
Annexin A1
|
Zeta Corporation |
ZM211 |
0.1 ml |
Concentrate |
CE/IVD |
Z2488MT |
-
|
Host |
Mouse |
Clone |
1/A5F6 |
Format |
Purified |
Method |
F, P, EL, WB, IP |
Pretreatment |
Citrate |
Positive control |
Kidney |
Dilution |
1:500 - 1:1000 (P) |
Isotype |
Mouse IgG1 |
Immunogen |
Synthetic peptide corresponding to amino acids 249-269 of rat aquaporin 1 |
Aquaporin 1
|
Zytomed Systems |
1/A5F6 |
100 µg (100 µl) |
Purified |
RUO |
601-0278 |
-
|
Host |
Rabbit |
Clone |
SP156 |
Format |
Concentrate |
Reactivity |
BV,PG,RB |
Method |
P |
Pretreatment |
EDTA |
Dilution |
1:100 |
Immunogen |
Synthetic peptide derived from the C-terminus of human arginase-1 protein |
Arginase-1
|
Zytomed Systems |
SP156 |
0.1 ml |
Concentrate |
RUO |
501-4560 |
-
|
Host |
Rabbit |
Clone |
SP156 |
Format |
Concentrate |
Reactivity |
BV,PG,RB |
Method |
P |
Pretreatment |
EDTA |
Dilution |
1:100 |
Immunogen |
Synthetic peptide derived from the C-terminus of human arginase-1 protein |
Arginase-1
|
Zytomed Systems |
SP156 |
0.5 ml |
Concentrate |
RUO |
501-4562 |
-
|
Host |
Rabbit |
Clone |
SP156 |
Format |
Concentrate |
Reactivity |
BV, PG, RB |
Method |
P |
Pretreatment |
EDTA |
Dilution |
1:100 |
Immunogen |
Synthetic peptide derived from the C-terminus of human arginase-1 protein |
Arginase-1
|
Zytomed Systems |
SP156 |
1 ml |
Concentrate |
RUO |
501-4564 |
-
|
Host |
Rabbit |
Clone |
EP261 |
Format |
Concentrate |
Method |
P |
Pretreatment |
Citrate |
Positive control |
Normal human liver |
Dilution |
1:100 |
Isotype |
Rabbit IgG |
Localization |
Cytoplasma and nucleus |
Arginase-1
|
Biocare Medical |
EP261 |
0.1 ml |
Concentrate |
CE/IVD |
ACI3058A |
-
|
Host |
Rabbit |
Clone |
EP261 |
Format |
Concentrate |
Method |
P |
Pretreatment |
Citrate |
Positive control |
Normal human liver |
Dilution |
1:100 |
Isotype |
Rabbit IgG |
Localization |
Cytoplasma and nucleus |
Arginase-1
|
Biocare Medical |
EP261 |
0.5 ml |
Concentrate |
CE/IVD |
ACI3058B |
-
|
Host |
Rabbit |
Clone |
EP261 |
Format |
Ready-to-use |
Method |
P |
Pretreatment |
Citrate |
Positive control |
Normal human liver |
Dilution |
- |
Isotype |
Rabbit IgG |
Localization |
Cytoplasmic and nuclear |
Arginase-1
|
Biocare Medical |
EP261 |
6 ml |
Ready-to-use |
CE/IVD |
API3058AA |
-
|
Host |
Rabbit |
Clone |
polyclonal |
Format |
Purified |
Method |
WB, P |
Pretreatment |
keine |
Positive control |
Herz |
Dilution |
5 µg/mL |
Isotype |
Rabbit IgG |
Immunogen |
Synthetic peptide corresponding to a portion of the amino acid sequence between 300-450 of human ATG4-KLH conjugated |
ATG4B
|
Zytomed Systems |
polyclonal |
50 µg |
Purified |
RUO |
601-0367 |
-
|
Host |
Rabbit |
Clone |
polyclonal |
Format |
concentrate |
Method |
P |
Pretreatment |
Citrate |
Positive control |
Normal prostate |
Dilution |
1:100 |
Isotype |
Rabbit IgG |
Localization |
nucear |
ATRX
|
Biocare Medical |
polyclonal |
0.1 ml |
concentrate |
CE/IVD |
ACI3251A |
-
|
Host |
Rabbit |
Clone |
polyclonal |
Format |
concentrate |
Method |
P |
Pretreatment |
Citrate |
Positive control |
Normal prostate |
Dilution |
1:100 |
Isotype |
Rabbit IgG |
Localization |
nucear |
ATRX
|
Biocare Medical |
polyclonal |
1 ml |
concentrate |
CE/IVD |
ACI3251C |
-
|
Host |
Rabbit |
Clone |
polyclonal |
Format |
Ready-to-use |
Method |
P |
Pretreatment |
Citrate |
Positive control |
Normal prostate |
Dilution |
- |
Isotype |
Rabbit IgG |
Localization |
nucear |
ATRX
|
Biocare Medical |
polyclonal |
7 ml |
Ready-to-use |
CE/IVD |
ALI3251G7 |
-
|
Host |
Rabbit |
Clone |
polyclonal |
Format |
Ready-to-use |
Method |
P |
Pretreatment |
Citrate |
Positive control |
Normal prostate |
Dilution |
- |
Isotype |
Rabbit IgG |
Localization |
nucear |
ATRX
|
Biocare Medical |
polyclonal |
6 ml |
Ready-to-use |
CE/IVD |
API3251AA |
-
|
Host |
Rabbit |
Clone |
polyclonal |
Format |
Ready-to-use |
Method |
P |
Pretreatment |
Citrate |
Positive control |
Normal prostate |
Dilution |
- |
Isotype |
Rabbit IgG |
Localization |
nucear |
ATRX
|
Biocare Medical |
polyclonal |
6 ml |
Ready-to-use |
CE/IVD |
AVI3251G |
-
|
Host |
Mouse |
Clone |
D-5 |
Format |
Concentrate |
Method |
F, P |
Pretreatment |
EDTA Puffer, pH 8,0 |
Positive control |
Pancreas |
Dilution |
1:50 - 1:100 |
Isotype |
Mouse IgG2a kappa |
Immunogen |
raised against amino acids 2193- 2492 mapping near the Cterminus of ATRX of human origin |
Localization |
nuclear |
ATRX
|
Diagnostic Biosystems |
D-5 |
1 ml |
Concentrate |
CE/IVD |
MOB600 |
-
|
Host |
Mouse |
Clone |
D-5 |
Format |
ready-to-use |
Method |
F, P |
Pretreatment |
EDTA Puffer, pH 8,0 |
Positive control |
Pancreas |
Dilution |
--- |
Isotype |
Mouse IgG2a kappa |
Immunogen |
raised against amino acids 2193- 2492 mapping near the Cterminus of ATRX of human origin |
Localization |
nuclear |
ATRX
|
Diagnostic Biosystems |
D-5 |
6 ml |
ready-to-use |
CE/IVD |
PDM600 |
-
|
Host |
Mouse |
Clone |
35C1 |
Format |
Purified |
Method |
WB, IP, IF |
Isotype |
Mouse IgG2b |
Immunogen |
Recombinant Aurora-A |
Aurora A Kinase
|
Zytomed Systems |
35C1 |
100 µg |
Purified |
RUO |
601-0320 |
-
|
Host |
Mouse |
Clone |
2213 |
Format |
Purified |
Method |
EL |
Isotype |
Mouse IgG1 |
Immunogen |
Highly pure beta-2-microglobulin from human urine |
b2-Microglobulin
|
Zytomed Systems |
2213 |
1 mg |
Purified |
RUO |
602-0004 |
-
|
Host |
Mouse |
Clone |
B2M-01 |
Format |
Purified |
Method |
EL, FL |
Isotype |
Mouse IgG2a |
Immunogen |
Beta-2-microglobulin from human urine |
b2-Microglobulin
|
Zytomed Systems |
B2M-01 |
250 µg |
Purified |
RUO |
602-0005 |
-
|
Host |
Mouse |
Clone |
TLD-3H12B |
Format |
Purified |
Method |
F, WB, FL |
Isotype |
Mouse IgG1 |
Immunogen |
Rat microglial cells |
b2-Microglobulin
|
Zytomed Systems |
TLD-3H12B |
250 µg |
Purified |
RUO |
602-0007 |
-
|
Host |
Mouse |
Clone |
TLD-3H12B |
Format |
Purified |
Method |
F, WB, FL |
Isotype |
Mouse IgG1 |
Immunogen |
Rat microglial cells |
b2-Microglobulin
|
Zytomed Systems |
TLD-3H12B |
100 µg |
Purified |
RUO |
602-0008 |
-
|
Host |
Rabbit |
Clone |
polyclonal |
Format |
Concentrate |
Method |
P |
Pretreatment |
EDTA |
Positive control |
Mesothelioma, Melanoma, Normal testis |
Dilution |
1:50 |
Isotype |
Rabbit IgG |
Localization |
Nuclear |
BAP1
|
Biocare Medical |
polyclonal |
0.1 ml |
Concentrate |
CE/IVD |
ACI3247A |
-
|
Host |
Rabbit |
Clone |
polyclonal |
Format |
Concentrate |
Method |
P |
Pretreatment |
EDTA |
Positive control |
Mesothelioma, Melanoma, Normal testis |
Dilution |
1:50 |
Isotype |
Rabbit IgG |
Localization |
Nuclear |
BAP1
|
Biocare Medical |
polyclonal |
0.5 ml |
Concentrate |
CE/IVD |
ACI3247B |
-
|
Host |
Rabbit |
Clone |
polyclonal |
Format |
Ready-to-use |
Method |
P |
Pretreatment |
EDTA |
Positive control |
Mesothelioma, Melanoma, Normal testis |
Dilution |
- |
Isotype |
Rabbit IgG |
Localization |
Nuclear |
BAP1
|
Biocare Medical |
polyclonal |
7 ml |
Ready-to-use |
CE/IVD |
ALI3247G7 |
-
|
Host |
Rabbit |
Clone |
polyclonal |
Format |
Ready-to-use |
Method |
P |
Pretreatment |
EDTA |
Positive control |
Mesothelioma, Melanoma, Normal testis |
Dilution |
- |
Isotype |
Rabbit IgG |
Localization |
Nuclear |
BAP1
|
Biocare Medical |
polyclonal |
6 ml |
Ready-to-use |
CE/IVD |
API3247AA |
-
|
Host |
Rabbit |
Clone |
ZR454 |
Format |
Ready-to-use |
Reactivity |
- |
Method |
P |
Pretreatment |
Citrate or EDTA |
Positive control |
Malignant Mesothelioma |
Dilution |
RTU |
Isotype |
IgG |
Immunogen |
Synthetic peptide against 430-729 of human BAP1 |
Localization |
Nuclear |
BAP1
|
Zeta Corporation |
ZR454 |
7.0 ml |
Ready-to-use |
RUO |
Z2813RP-R |
-
|
Host |
Rabbit |
Clone |
ZR454 |
Format |
Concentrate |
Reactivity |
- |
Method |
P |
Pretreatment |
Citrate or EDTA |
Positive control |
Malignant Mesothelioma |
Dilution |
1:100-20 |
Isotype |
IgG |
Immunogen |
Synthetic peptide against 430-729 of human BAP1 |
Localization |
Nuclear |
BAP1
|
Zeta Corporation |
ZR454 |
0.5 ml |
Concentrate |
RUO |
Z2813RS-R |
-
|
Host |
Mouse |
Clone |
C-4 |
Format |
ready-to-use |
Method |
FFPE |
Pretreatment |
EDTA |
Positive control |
Breast Carcinoma |
Dilution |
--- |
Isotype |
IgG1, kappa |
Immunogen |
Synthetic peptide against 430-729 of human BAP1 |
Localization |
nuclear and cytoplasmic |
BAP1 (BRCA1-Associated Protein 1)
|
Diagnostic Biosystems |
C-4 |
6 ml |
ready-to-use |
CE/IVD |
PDM595 |
-
|
Host |
Rabbit |
Clone |
SP47 |
Format |
Concentrate |
Method |
P |
Pretreatment |
Citrate |
Positive control |
Hodgkin´s Lymphoma |
Dilution |
1:50 |
Isotype |
Rabbit IgG |
Immunogen |
Synthetic peptide derived from N-terminal of human Bak. |
Localization |
Cytoplasm, Cell Membrane |
Bax
|
Zytomed Systems |
SP47 |
0.5 ml |
Concentrate |
RUO |
502-3472 |
-
|
Host |
Rabbit |
Clone |
SP47 |
Format |
Concentrate |
Method |
P |
Pretreatment |
Citrate |
Positive control |
Hodgkin´s Lymphoma |
Dilution |
1:50 |
Isotype |
Rabbit IgG |
Immunogen |
Synthetic peptide derived from N-terminal of human Bak. |
Localization |
Cytoplasm, Cell Membrane |
Bax
|
Zytomed Systems |
SP47 |
1 ml |
Concentrate |
RUO |
502-3474 |
-
|
Host |
Mouse |
Clone |
Cu-18 |
Format |
Concentrate |
Method |
P |
Pretreatment |
Citrate |
Positive control |
Breast cancer, Lung cancer, Ovarian cancer, Endometrial cancer |
Dilution |
1:100 |
Isotype |
Mouse IgG1 |
Localization |
Cytoplasmic |
BCA-225
|
Biocare Medical |
Cu-18 |
0.1 ml |
Concentrate |
CE/IVD |
ACI3241A |
-
|
Host |
Mouse |
Clone |
Cu-18 |
Format |
Concentrate |
Method |
P |
Pretreatment |
Citrate |
Positive control |
Breast cancer, Lung cancer, Ovarian cancer, Endometrial cancer |
Dilution |
1:100 |
Isotype |
Mouse IgG1 |
Localization |
Cytoplasmic |
BCA-225
|
Biocare Medical |
Cu-18 |
0.5 ml |
Concentrate |
CE/IVD |
ACI3241B |
-
|